Hospital
Springfield Health Services, LLC
Springfield Health Services, LLC was paid $3.92M by Medicaid between Sep 2021 and Dec 2024, across 60 billing codes. Its largest line is 99283, emergency room visit (moderate) — 38% of everything it billed.
33Billing provider infoSPRINGFIELD HEALTH SERVICES, LLC
SPRINGFIELD, TN 37172
SPRINGFIELD, TN 37172
33aNPI1093397184assigned 04/27/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.92M
24GClaims90,046
24DCodes billed60
24AFirst – last monthSep 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#49 of 71
Median peer was paid$6.96M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 9,317 | $370K | |
| 2022 | 30,906 | $1.32M | |
| 2023 | 28,276 | $1.20M | |
| 2024incomplete | 21,547 | $1.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 38% | 11,697 | 10,250 | $1.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 9,364 | 7,651 | $1.25M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.3% | 5,155 | 4,244 | $286K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.0% | 4,163 | 3,642 | $156K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 463 | 315 | $109K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.6% | 3,488 | 3,169 | $103K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 885 | 807 | $101K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 1,208 | 969 | $75K |
| G0378 | Hospital observation service, per hour | 1.4% | 449 | 266 | $53K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 1,096 | 366 | $45K |
| 85027 | <1% | 10,916 | 8,327 | $30K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 600 | 510 | $29K |
48 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,289 | $25K |
| 80053 | Comprehensive metabolic panel | <1% | 9,400 | $23K |
| 84484 | <1% | 2,789 | $23K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 629 | $15K |
| 87634 | <1% | 291 | $10K | |
| 83605 | <1% | 2,103 | $10K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,323 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,232 | $9K |
| 83690 | <1% | 2,388 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,239 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 60 | $6K |
| 85730 | <1% | 2,146 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 312 | $4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 89 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 206 | $3K |
| 85610 | <1% | 2,256 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 498 | $2K |
| 81025 | <1% | 856 | $2K | |
| 87070 | <1% | 220 | $1K | |
| 81001 | <1% | 1,780 | $1K | |
| 83880 | <1% | 115 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 199 | $998.12 |
| 81003 | <1% | 1,444 | $568.59 | |
| 83735 | <1% | 225 | $551.59 | |
| 82803 | <1% | 55 | $475.22 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 101 | $426.69 |
| 94729 | <1% | 45 | $386.72 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 303 | $313.74 |
| 94727 | <1% | 49 | $303.20 | |
| 87040 | <1% | 82 | $275.19 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $251.76 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 188 | $210.19 |
| 84703 | <1% | 39 | $198.45 | |
| 82077 | <1% | 48 | $170.92 | |
| 83874 | <1% | 37 | $114.30 | |
| 80179 | <1% | 32 | $114.10 | |
| 80143 | <1% | 32 | $114.10 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 262 | $104.04 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 33 | $77.20 |
| 87807 | <1% | 14 | $58.83 | |
| 80076 | <1% | 50 | $52.80 | |
| 59025 | Fetal non-stress test | <1% | 14 | $44.79 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $18.88 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 266 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 307 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 48 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 261 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 178 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIGGERS, HALEY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hca Health Services of New Hampshire INC | Portsmouth, NH | $18.83M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.